NAION & Ozempic Lawsuit – Vision Loss Claims & Free Case Review
If you took Ozempic, Wegovy, or another GLP-1 drug and were diagnosed with NAION (sudden vision loss), you may qualify for a free case review. Lawsuits allege manufacturers failed to warn about the risk of Non-Arteritic Anterior Ischemic Optic Neuropathy. Confidential, no obligation.
Top Tier Legal LLC is not a law firm and does not provide legal advice. Submitting does not create an attorney-client relationship. If we share your information with a law firm, it is for evaluation only; the firm will independently decide whether to contact you. Outcomes are not guaranteed.
Top Tier Legal LLC is not a law firm and does not provide legal advice. Submitting does not create an attorney-client relationship. If we share your information with a law firm, it is for evaluation only; the firm will independently decide whether to contact you. Outcomes are not guaranteed.
You may qualify if:
- You took Ozempic, Wegovy, Saxenda, Mounjaro, Zepbound, or another GLP-1 (semaglutide / tirzepatide) drug
- You were diagnosed with NAION (Non-Arteritic Anterior Ischemic Optic Neuropathy) or sudden vision loss
- Vision loss or NAION occurred after starting the medication
- Statutes of limitations vary by state—contact us soon
You can submit even if you don't have all records yet.
NAION & Ozempic Lawsuit News & Updates HubWho May Qualify
You may be eligible for a free NAION / Ozempic legal case review if you took a GLP-1 medication (such as Ozempic, Wegovy, Saxenda, Mounjaro, or Zepbound) and were later diagnosed with NAION—Non-Arteritic Anterior Ischemic Optic Neuropathy—or experienced sudden, painless vision loss. The following factors may indicate eligibility:
- Used Ozempic, Wegovy, Saxenda, Mounjaro, Zepbound, or another semaglutide or tirzepatide product
- Diagnosed with NAION or sudden vision loss (optic nerve damage)
- Vision loss or NAION occurred after starting the medication
- Prescribed for type 2 diabetes or weight loss
If you believe you may qualify, we encourage you to submit your information for a free case review. Our review process helps determine if you may be connected with an independent law firm for evaluation of a potential claim.
What is NAION?
Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) is sudden, painless, and often permanent vision loss caused by reduced blood flow to the optic nerve. It affects tens of thousands of Americans each year and, in many cases, there is no guaranteed treatment that restores vision.
NAION symptoms can be easy to miss at first—especially when the loss is painless. Many people notice changes such as a dark spot in the visual field, blurred central vision, or difficulty seeing objects on one side. In many cases, the vision loss develops over hours to days and can become permanent without timely evaluation.
- Sudden blur, dimming, or loss of vision—often in one eye
- A dark spot, “curtain,” or missing visual field area
- Usually painless—so warning signs may be delayed
- May be permanent, with limited recovery for many patients
For people using GLP-1 medications like Ozempic and Mounjaro, NAION is a serious concern because it can cause long-term vision impairment. Lawsuits allege these manufacturers failed to provide adequate warnings and that some patients and doctors were not informed about this risk when making treatment decisions.
The Link Between GLP-1 Drugs and NAION
A July 2024 study published in JAMA Ophthalmology (Harvard-affiliated researchers) found that users of semaglutide had a significantly elevated risk of NAION: about 4.28 times higher for people with type 2 diabetes and about 7.64 times higher for those using the drug for weight loss, compared to non-users.
In June 2025, the European Medicines Agency (EMA) added NAION as a "very rare" side effect for semaglutide-containing medicines. The FDA had not added a NAION warning to U.S. labels as of early 2026—a gap that is central to plaintiffs' failure-to-warn claims.
Importantly, risk statistics are not the same as “certainty.” A higher relative risk means the chance may be greater than it would be for someone not using the medication—not that NAION will happen to every patient. Plaintiffs argue that even a rare outcome should be described clearly so doctors and patients can weigh benefits against potential harms, especially when symptoms like sudden vision loss warrant prompt care.
Which Drugs Are Involved?
Ozempic / Wegovy
Semaglutide (Novo Nordisk)—type 2 diabetes and weight loss
Saxenda
Liraglutide (Novo Nordisk)—weight loss
Mounjaro / Zepbound
Tirzepatide (Eli Lilly)—type 2 diabetes and weight loss
Trulicity
Dulaglutide (Eli Lilly)—type 2 diabetes
Get the full picture: MDL status, key dates, science & FAQ
NAION & Ozempic Lawsuit News & Updates HubNAION / Ozempic MDL & Litigation Updates
Federal lawsuits alleging that Ozempic and other GLP-1 drugs caused NAION (vision loss) are consolidated in MDL No. 3163, In re: GLP-1 RA Products Liability Litigation (No. II), in the Eastern District of Pennsylvania under Judge Karen S. Marston. The MDL was created in December 2025. Plaintiffs allege that Novo Nordisk and Eli Lilly failed to warn about the risk of NAION. Additional cases are pending in state court, including in New Jersey.
Current Status
- Federal NAION/GLP-1 cases centralized in MDL 3163 (E.D. Pa.)
- Litigation is in early stages; discovery and bellwether planning ongoing
- EMA added NAION as very rare side effect (June 2025); FDA label update pending
- Statutes of limitations vary by state—contact us for a free case review
Time limits may apply. Submit your information for a free, confidential case review to see if you may qualify to be connected with a law firm handling these claims.
Legal Rights for Affected Patients
If you took Ozempic or another GLP-1 and later developed NAION or sudden, painless vision loss, you may have legal options. Most of these matters are processed through a coordinated mass-tort structure—meaning the cases share common scientific and legal issues, while each claimant’s experience is still considered individually.
In a legal review, an attorney typically examines key factors such as: your diagnosis details, the timing between medication use and symptom onset, evidence of the GLP-1 drug exposure, and documentation showing how the vision loss affected your life. Statutes of limitations vary by state, so acting sooner can help preserve records and strengthen the case.
What you can do right now
- Document your timeline (start date, dose changes, and when vision symptoms began)
- Collect key medical records and prescription/pharmacy documents
- Start a free case review so counsel can evaluate eligibility
Projected NAION / Ozempic Settlement Amounts
No settlements have been reached yet. Based on similar drug injury and vision-loss cases, lawyers and analysts estimate potential compensation ranges by severity. Outcomes depend on litigation developments and your individual facts.
If a case resolves through settlement or verdict, potential damages often focus on the harm caused by the vision loss. That can include medical expenses, ongoing treatment and vision rehabilitation, lost wages or reduced earning capacity, and the non-economic impact of living with permanent vision impairment. Your results will depend on the severity of NAION, the timeline of symptoms, and the strength of the medical documentation.
| Severity | Description | Estimated Range |
|---|---|---|
| High Severity | Bilateral NAION, severe permanent vision loss or legal blindness | $1,500,000 – $3,000,000+ |
| Moderate–High | Unilateral NAION with significant permanent vision loss | $300,000 – $800,000 |
| Moderate | Unilateral NAION with partial vision loss, impact on daily life | $150,000 – $400,000 |
These are estimates only. No guarantee of recovery. Law firms typically work on contingency—you generally pay only if there is a recovery.
How to File a NAION & Ozempic Lawsuit
While every case is different, the process usually follows a predictable path. The goal is to document your diagnosis, prove exposure to the GLP-1 medication, and connect the timing of vision symptoms to the medication history.
- Review your timeline. Note when you started (and if relevant, when you changed) Ozempic or another GLP-1, and the date when you first noticed vision symptoms.
- Gather medical and pharmacy records. Collect ophthalmology/optometry records, diagnosis documentation, and records showing your prescriptions or pharmacy fill history.
- Submit a free case review. Share the information you have. If you don’t have everything yet, that’s okay—you can start the review now.
- Attorney eligibility screening. Counsel typically evaluates whether your facts match the NAION / GLP-1 legal criteria and which coordinated docket (such as MDL proceedings) may be involved.
- Litigation and evidence development. Your legal team may request additional documentation and help prepare for discovery, medical record verification, and other pretrial steps.
- Resolution. Cases may resolve through settlement discussions or proceed toward trial depending on the posture of the litigation and the specific proof in your record.
The most useful documents often include
- NAION diagnosis documentation (or records describing sudden, painless vision loss)
- Ophthalmology exam notes, imaging, and visual field/optic nerve testing where available
- Prescription history for Ozempic/Wegovy/Saxenda/Mounjaro/Zepbound and any dose-change records
Evidence Linking GLP-1 Drugs to NAION
Peer-reviewed research has raised concerns about an association between GLP-1 receptor agonists (e.g., semaglutide) and NAION. Plaintiffs allege that manufacturers knew or should have known of this risk and failed to warn.
JAMA Ophthalmology (July 2024)
A study of 16,827 patients found that semaglutide users had a significantly higher cumulative incidence of NAION (8.9%) compared to non-users (1.8%). For people with type 2 diabetes, the risk was about 4.28 times higher; for those using semaglutide for weight loss, the risk was about 7.64 times higher.
Key finding: 4.28x–7.64x increased NAION risk with semaglutide
European Medicines Agency (June 2025)
The EMA added NAION as a "very rare" side effect to the product information for semaglutide-containing medicines (e.g., Ozempic, Wegovy). This regulatory action supports allegations that the risk was known or knowable and that U.S. labeling should have been updated.
Key finding: EMA recognizes NAION as very rare adverse effect
These types of findings are part of what attorneys review when assessing potential failure-to-warn claims. Your medical records help determine how your NAION diagnosis, vision loss severity, and timeline connect to your GLP-1 medication exposure.
FAQs About Ozempic and NAION Lawsuits
Common questions from people who took Ozempic or another GLP-1 and later experienced NAION or sudden, painless vision loss.
Contacting a Legal Expert
If you think your vision loss may be connected to Ozempic or another GLP-1 medication, consider speaking with an attorney experienced in mass-tort drug injury matters. A free case review can help you understand your options and what information is needed to move forward.
Start with the form below
Submitting does not create an attorney-client relationship unless a law firm decides to proceed. If you prefer, you can also use our contact page to reach our team.
NAION / Ozempic Litigation & Legal Resources
If you took Ozempic, Wegovy, or another GLP-1 drug and were diagnosed with NAION or sudden vision loss, a free case review can help you understand your options and whether you may be connected with a law firm handling these claims.
Latest MDL status, key dates, and legal developments.
Overview of dangerous drug claims and how we connect you with law firms.
Legal disclaimer
Top Tier Legal LLC is not a law firm and does not provide legal advice. Submitting does not create an attorney-client relationship. If we share your information with a law firm, it is for evaluation only; the firm will independently decide whether to contact you. Outcomes are not guaranteed.
Related Posts
Start Your Free NAION / Ozempic Case Review
Time limits may apply. If you took Ozempic or another GLP-1 drug and were diagnosed with NAION or sudden vision loss, contact us today for a free, confidential case review to see if you may qualify and be connected with a law firm handling these claims.